Open Access Open Access  Restricted Access Subscription or Fee Access

Successful use of buprenorphine-naloxone medication-assisted program to treat concurrent pain and opioid addiction after cancer therapy

Natalie Moryl, MD, Alexandra Filkins, Yvona Griffo, MD, Vivek Malhotra, MD, Raina H. Jain, Ethel Frierson, RN, BSN, OCN, Charles Inturrisi, PhD

Abstract


Cancer pain is often treated with opioids, a therapeutic regimen that can become a challenge in patients with an opioid use disorder (OUD). While use of the buprenorphine-naloxone combination is an effective medication-assisted treatment (MAT) for OUD, its use in pain patients with OUD has been controversial due to concerns that co-administration of buprenorphine can reduce or block analgesia and precipitate opioid withdrawal in those patients requiring full opioid agonists. Data on its use in cancer pain patients are lacking. In this case series, the authors explore the frequency of buprenorphine-naloxone use and its outcomes in patients in a Comprehensive Care Center (CCC) Pain Registry. OUD was deduced from an International Classification of Diseases (ICD-10) diagnostic code for opioid-related disorders recorded in the electronic medical records. Of 2,320 chronic cancer pain patients, 125 patients had ICD-10 code for opioid-related disorders, and 43 had a diagnosis of opioid abuse of whom 11 received buprenorphinenaloxone combinations. Eight patients on 18 (6-24) mg per day of buprenorphinenaloxone remained in therapy for 4 (2-7) years without opioid abuse relapse. This assessment was based on clinician's notes, the Prescription Monitoring Program, random urine drug screening, and the absence of Urgent Care Center visits for opioid withdrawal or overdose. When short-term opioids were administered for acute pain, these patients were able to taper down and stop them quickly without an opioid abuse relapse. Buprenorphine-naloxone was effective as the sole analgesic in selected patients. Given its success at the CCC, buprenorphine-naloxone should be made available and strongly considered as a treatment for patients suffering from OUD during and following cancer treatment and when cancer pain reduces or resolves.


Keywords


Suboxone, addiction, cancer, co-management, pain, survivors

Full Text:

PDF

References


van den Beuken-van MH, Hochstenbach LM, Joosten EA, et al.: Update on prevalence of pain in patients with cancer: Systematic review and meta-analysis. J Pain Symptom Manage. 2016; 51(6): 1070-1090.

Swarm RA, Paice JA, Anghelescu DL, et al.: Adult cancer pain, Version 1.2019. NCCN Clinical Practice Guidelines in Oncology. Available at www.nccn.org. Accessed January 25, 2019.

Dowell D, Haegerich TM, Chou R: CDC guideline for prescribing opioids for chronic pain--United States. JAMA. 2016; 315(15): 1624-1645.

Congressional Research Service: Buprenorphine and the opioid crisis: A primer for Congress. Available at https://fas.org/sgp/crs/misc/R45279.pdf. Accessed February 24, 2019.

Ahn JS, Lin J, Ogawa S, et al.: Transdermal buprenorphine and fentanyl patches in cancer pain: A network systematic review. J Pain Res. 2017; 10: 1963-1972.

Mercadante S, Casuccio A, Tirelli W, et al.: Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Support Care Cancer. 2009; 17(6): 715-718.

Freye E, Anderson-hillemacher A, Ritzdorf I, et al.: Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec®) in chronic pain patients. Pain Pract. 2007; 7(2): 123-129.

Sittl R, Likar R, Nautrup BP: Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: Results of a retrospective cohort study. Clin Ther. 2005; 27(2): 225-237.

Golcčić M, Dobrila-Dintinjana R, Golcčić G, et al.: Differences between transdermal fentanyl and buprenorphine in the elderly hospice patients. Pain Res Treat. 2018; 2018: 8610538.

Gowing L, Ali R, White JM, et al.: Buprenorphine for managing opioid withdrawal. Cochrane Database Syst Rev. 2017; 2: 1-78.

Office of the Assistant Secretary: Review of medication-assisted treatment guidelines and measures for opioid and alcohol use. Available at https://aspe.hhs.gov/report/review-medication-assisted-treatment-guidelines-and-measures-opioidand-alcohol-use. Accessed February 24, 2019.

Davenport S, Matthews K: Opioid use disorder in the United States: Diagnosed prevalence by payer, age, sex, and state. Milliman White Paper. March 9, 2018. Available at http://www.milliman.com/insight/2018/Opioid-use-disorder-in-the-United-States-Diagnosed-prevalence-by-payer--age--sex--and-state/. Accessed January 2, 2020.

Horn SD, DeJong G, Deutscher D: Practice-based evidence research in rehabilitation: An alternative to randomized controlled trials and traditional observational studies. Arch Phys Med Rehabil. 2012; 93: S127-S137.

Horn SD, Gassaway J: Practice-based evidence study design for comparative effectiveness research. Med Care. 2007; 45(10 suppl 2): S50-S57.

Moryl N, Dave V, Glare P, et al.: Patient-reported outcomes and opioid use by outpatient cancer patients. J Pain. 2018; 19: 278-290.

Malhotra VT, Glare P, Tan KS, et al.: The tri-institutional pain registry--Analysis of outpatient pain management at a specialized cancer center. Pain Med. 2017; 18(12): 2474-2484.

Mattick RP, Breen C, Kimber J, et al.: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003; (2): CD002209.




DOI: https://doi.org/10.5055/jom.2020.0557

Refbacks

  • There are currently no refbacks.